Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

CVRx, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MINNEAPOLIS, OCT. 22, 2025 (GLOBE NEWSWIRE) -- CVRX, INC. (NASDAQ: CVRX) ("CVRX"), A COMMERCIAL-STAGE MEDICAL DEVICE COMPANY FOCUSED ON DEVELOPING, MANUFACTURING AND COMMERCIALIZING INNOVATIVE NEUROMODULATION SOLUTIONS FOR PATIENTS WITH CARDIOVASCULAR DISEASES, TODAY ANNOUNCED THAT IT PLANS TO RELEASE THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS AFTER MARKET CLOSE ON WEDNESDAY, NOV. 5, 2025. THE COMPANY WILL HOST A CONFERENCE CALL TO REVIEW ITS RESULTS AT 4:30 P.M. EASTERN TIME THE SAME DAY. A LIVE WEBCAST OF THE INVESTOR CONFERENCE CALL WILL BE AVAILABLE ONLINE AT THE INVESTOR RELATIONS PAGE OF THE COMPANY'S WEBSITE AT IR.CVRX.COM. TO LISTEN TO THE CONFERENCE CALL ON YOUR TELEPHONE, PLEASE DIAL 1- 877-704-4453 FOR U.S. CALLERS, OR 1-201-389-0920 FOR INTERNATIONAL CALLERS, APPROXIMATELY TEN MINUTES PRIOR TO THE START TIME.

CVRX TO REPORT THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS AND HOST CONFERENCE CALL ON NOV. 5, 2025

MINNEAPOLIS, AUG. 04, 2025 (GLOBE NEWSWIRE) -- CVRX, INC. (NASDAQ: CVRX) ("CVRX"), A COMMERCIAL-STAGE MEDICAL DEVICE COMPANY FOCUSED ON DEVELOPING, MANUFACTURING AND COMMERCIALIZING INNOVATIVE NEUROMODULATION SOLUTIONS FOR PATIENTS WITH CARDIOVASCULAR DISEASES, TODAY ANNOUNCED ITS FINANCIAL AND OPERATING RESULTS FOR THE SECOND QUARTER OF 2025.

CVRX REPORTS SECOND QUARTER 2025 FINANCIAL AND OPERATING RESULTS

MINNEAPOLIS, JULY 29, 2025 (GLOBE NEWSWIRE) -- CVRX, INC. (NASDAQ: CVRX) ("CVRX"), A COMMERCIAL-STAGE MEDICAL DEVICE COMPANY FOCUSED ON DEVELOPING, MANUFACTURING AND COMMERCIALIZING INNOVATIVE NEUROMODULATION SOLUTIONS FOR PATIENTS WITH CARDIOVASCULAR DISEASES, TODAY ANNOUNCED THAT THE MANAGEMENT TEAM WILL PRESENT AT THE CANACCORD GENUITY 45TH ANNUAL GROWTH CONFERENCE ON TUESDAY, AUGUST 12, 2025. THE COMPANY IS SCHEDULED TO PRESENT AT 3:00PM EASTERN TIME THE SAME DAY VIA WEBCAST.

CVRX TO PRESENT AT THE CANACCORD GENUITY 45TH ANNUAL GROWTH CONFERENCE

MINNEAPOLIS, JULY 16, 2025 (GLOBE NEWSWIRE) -- CVRX, INC. (NASDAQ: CVRX) (CVRX), A COMMERCIAL-STAGE MEDICAL DEVICE COMPANY, ANNOUNCED TODAY THAT THE CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS) HAS PROPOSED TO KEEP THE BAROSTIM IMPLANT PROCEDURE AS PART OF THE NEW TECHNOLOGY AMBULATORY PAYMENT CLASSIFICATION (APC) 1580, WITH AN ASSOCIATED PAYMENT OF APPROXIMATELY $45,000 FOR PROCEDURES PERFORMED IN THE OUTPATIENT SETTING. CMS IS ALSO SOLICITING COMMENTS ABOUT THE NEED FOR A LEVEL 6 NEUROSTIMULATOR APC. WE EXPECT CMS WILL PUBLISH THE 2026 MEDICARE HOSPITAL OUTPATIENT PROSPECTIVE PAYMENT SYSTEM (OPPS) FINAL RULE IN NOVEMBER, WHICH IS EXPECTED TO TAKE EFFECT ON JANUARY 1, 2026.

CVRX ANNOUNCES POSITIVE NEWS ON OUTPATIENT PAYMENT FOR BAROSTIM

MINNEAPOLIS, MAY 28, 2025 (GLOBE NEWSWIRE) -- CVRX, INC. (NASDAQ: CVRX) ("CVRX"), A COMMERCIAL-STAGE MEDICAL DEVICE COMPANY FOCUSED ON DEVELOPING, MANUFACTURING AND COMMERCIALIZING INNOVATIVE NEUROMODULATION SOLUTIONS FOR PATIENTS WITH CARDIOVASCULAR DISEASES, TODAY ANNOUNCED THAT THE MANAGEMENT TEAM WILL PRESENT AT THE WILLIAM BLAIR 45TH ANNUAL GROWTH STOCK CONFERENCE ON WEDNESDAY, JUNE 4, 2025. THE COMPANY IS SCHEDULED TO PRESENT AT 10:00AM CENTRAL TIME THE SAME DAY VIA WEBCAST.

CVRX TO PRESENT AT THE WILLIAM BLAIR 45TH ANNUAL GROWTH STOCK CONFERENCE

MINNEAPOLIS, APRIL 24, 2025 (GLOBE NEWSWIRE) -- CVRX, INC. (NASDAQ: CVRX) ("CVRX"), A COMMERCIAL-STAGE MEDICAL DEVICE COMPANY, TODAY ANNOUNCED THAT IT PLANS TO RELEASE FIRST QUARTER 2025 FINANCIAL AND OPERATING RESULTS AFTER MARKET CLOSE ON THURSDAY, MAY 8, 2025. THE COMPANY WILL HOST A CONFERENCE CALL TO REVIEW ITS RESULTS AT4:30PM EASTERN TIMETHE SAME DAY.

CVRX TO REPORT FIRST QUARTER 2025 FINANCIAL AND OPERATING RESULTS AND HOST CONFERENCE CALL ON MAY 8, 2025

FIRST QUARTER REVENUE EXPECTED TO BE APPROXIMATELY $12.3 MILLION, REPRESENTING GROWTH OF APPROXIMATELY 15% OVER FIRST QUARTER 2024 FIRST QUARTER REVENUE EXPECTED TO BE APPROXIMATELY $12.3 MILLION, REPRESENTING GROWTH OF APPROXIMATELY 15% OVER FIRST QUARTER 2024

CVRX REPORTS PRELIMINARY FIRST QUARTER 2025 FINANCIAL RESULTS

NEW REAL-WORLD EVIDENCE PRESENTED AT THT 2025 AND PUBLISHED SIMULTANEOUSLY IN THE JOURNAL OF CARDIAC FAILURE (JCF) DEMONSTRATES LARGE AND STATISTICALLY SIGNIFICANT REDUCTIONS IN HOSPITAL VISITS AND LENGTH OF STAY IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION NEW REAL-WORLD EVIDENCE PRESENTED AT THT 2025 AND PUBLISHED SIMULTANEOUSLY IN THE JOURNAL OF CARDIAC FAILURE (JCF) DEMONSTRATES LARGE AND STATISTICALLY SIGNIFICANT REDUCTIONS IN HOSPITAL VISITS AND LENGTH OF STAY IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION

CVRX ANNOUNCES NEW REAL-WORLD EVIDENCE DEMONSTRATING SIGNIFICANT REDUCTIONS IN HEALTHCARE UTILIZATION WITH BAROSTIM

MINNEAPOLIS, FEB. 04, 2025 (GLOBE NEWSWIRE) -- CVRX, INC. ("CVRX"), A COMMERCIAL-STAGE MEDICAL DEVICE COMPANY FOCUSED ON DEVELOPING, MANUFACTURING AND COMMERCIALIZING INNOVATIVE NEUROMODULATION SOLUTIONS FOR PATIENTS WITH CARDIOVASCULAR DISEASES, TODAY ANNOUNCED ITS FINANCIAL AND OPERATING RESULTS FOR THE FOURTH QUARTER AND FULL YEAR OF 2024.

CVRX REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL AND OPERATING RESULTS

MINNEAPOLIS, JAN. 21, 2025 (GLOBE NEWSWIRE) -- CVRX, INC. (NASDAQ: CVRX) (CVRX), A COMMERCIAL-STAGE MEDICAL DEVICE COMPANY FOCUSED ON DEVELOPING, MANUFACTURING AND COMMERCIALIZING BAROSTIM, AN INNOVATIVE EXTRAVASCULAR IMPLANTABLE NEUROMODULATION DEVICE FOR PATIENTS WITH CARDIOVASCULAR DISEASES, TODAY ANNOUNCED THAT IT PLANS TO RELEASE FOURTH QUARTER 2024 FINANCIAL AND OPERATING RESULTS AFTER MARKET CLOSE ON TUESDAY, FEBRUARY 4, 2025. THE COMPANY WILL HOST A CONFERENCE CALL TO REVIEW ITS RESULTS AT4:30PM EASTERN TIMETHE SAME DAY.

CVRx, Inc.

CVRX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CVRx, Inc.

CVRX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CVRX